Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price traded down 8.7% during mid-day trading on Thursday . The company traded as low as $39.40 and last traded at $39.91. 135,550 shares were traded during trading, a decline of 85% from the average session volume of 899,470 shares. The stock had previously closed at $43.73.
Wall Street Analysts Forecast Growth
MTSR has been the subject of a number of recent research reports. Wells Fargo & Company assumed coverage on Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Guggenheim raised their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $55.00.
Read Our Latest Stock Report on MTSR
Metsera Trading Down 6.6%
The firm's 50-day moving average price is $30.49.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new stake in shares of Metsera during the 1st quarter worth approximately $76,000. New York State Common Retirement Fund acquired a new position in shares of Metsera during the 1st quarter worth $131,000. Corebridge Financial Inc. acquired a new position in shares of Metsera during the 1st quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Metsera during the 1st quarter worth $248,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Metsera during the 1st quarter worth $254,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access